How spirulina dose-dependently inhibits mast cell degranulation and reduces serum histamine levels — and why that mechanism matters for horses with hypersensitivity conditions.

Tufts University research shows quercetin outperforms cromolyn — the pharmaceutical mast cell stabilizer — in blocking mast cell cytokine and histamine release. We use the more bioavailable form: isoquercetin.

Why isoquercetin outperforms standard quercetin in bioavailability studies — 1.5× more absorbed — and what that means for horses that need systemic anti-allergic support.

The peer-reviewed evidence for methylsulfonylmethane in reducing inflammation across joint, airway, and dermal tissues. We use the pharmaceutical-grade distilled form: OptiMSM.

Generic MSM and OptiMSM® are not the same product. The distillation process affects purity, and purity affects what actually reaches the bloodstream.

Clinical trial data showing bromelain increases quercetin effectiveness — moving responder rates from 67% to 82% — and the mechanism behind why enzyme co-administration matters.

How spirulina and fat-soluble Vitamin C work together in the immune and antioxidant pathway — and why sourcing and form matter for bioavailability in lipid-rich tissues.

The inflammation pathway research on DHA — and why we chose algae-derived DHA over fish oil. Species-appropriate sourcing is not just a marketing position — there’s a physiological reason for it.